Vanguard Group
KALV

Vanguard Group’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40.5M Buy
2,509,020
+7,901
+0.3% +$105K ﹤0.01% 2281
2025
Q3 		$30.5M Buy
2,501,119
+88,720
+4% +$1.23M ﹤0.01% 2412
2025
Q2 		$27.3M Buy
2,412,399
+113,801
+5% +$1.39M ﹤0.01% 2408
2025
Q1 		$26.5M Buy
2,298,598
+43,355
+2% +$442K ﹤0.01% 2376
2024
Q4 		$19.1M Buy
2,255,243
+104,716
+5% +$1.08M ﹤0.01% 2610
2024
Q3 		$24.9M Buy
2,150,527
+159,939
+8% +$2.01M ﹤0.01% 2482
2024
Q2 		$23.4M Buy
1,990,588
+305,475
+18% +$3.56M ﹤0.01% 2490
2024
Q1 		$20M Sell
1,685,113
-96,306
-5% -$1.28M ﹤0.01% 2596
2023
Q4 		$21.8M Buy
1,781,419
+48,930
+3% +$445K ﹤0.01% 2555
2023
Q3 		$16.7M Buy
1,732,489
+151,808
+10% +$1.55M ﹤0.01% 2617
2023
Q2 		$14.2M Sell
1,580,681
-1,845
-0.1% -$17K ﹤0.01% 2750
2023
Q1 		$12.4M Buy
1,582,526
+429,853
+37% +$3.21M ﹤0.01% 2822
2022
Q4 		$7.79M Buy
1,152,673
+2,812
+0.2% +$15.1K ﹤0.01% 3067
2022
Q3 		$16.7M Sell
1,149,861
-7,297
-0.6% -$102K ﹤0.01% 2709
2022
Q2 		$11.4M Sell
1,157,158
-9,494
-0.8% -$105K ﹤0.01% 2921
2022
Q1 		$17.2M Buy
1,166,652
+28,168
+2% +$405K ﹤0.01% 2854
2021
Q4 		$15.1M Sell
1,138,484
-48,263
-4% -$768K ﹤0.01% 2988
2021
Q3 		$20.7M Buy
1,186,747
+222,328
+23% +$4.51M ﹤0.01% 2846
2021
Q2 		$23.1M Buy
964,419
+34,938
+4% +$914K ﹤0.01% 2765
2021
Q1 		$23.9M Buy
929,481
+361,933
+64% +$9.51M ﹤0.01% 2693
2020
Q4 		$10.8M Buy
567,548
+8,695
+2% +$149K ﹤0.01% 2957
2020
Q3 		$7.04M Sell
558,853
-479
-0.1% -$5.99K ﹤0.01% 2974
2020
Q2 		$6.77M Sell
559,332
-861
-0.2% -$9.16K ﹤0.01% 2948
2020
Q1 		$4.29M Buy
560,193
+10,174
+2% +$137K ﹤0.01% 3035
2019
Q4 		$9.79M Buy
550,019
+5,971
+1% +$77.9K ﹤0.01% 2868
2019
Q3 		$6.31M Buy
544,048
+16,219
+3% +$262K ﹤0.01% 3047
2019
Q2 		$11.7M Buy
527,829
+170,439
+48% +$4M ﹤0.01% 2773
2019
Q1 		$10.2M Buy
357,390
+16,547
+5% +$359K ﹤0.01% 2810
2018
Q4 		$6.73M Buy
340,843
+44,262
+15% +$890K ﹤0.01% 2950
2018
Q3 		$6.56M Buy
296,581
+179,092
+152% +$2.42M ﹤0.01% 3135
2018
Q2 		$954K Buy
117,489
+394
+0.3% +$3.48K ﹤0.01% 3702
2018
Q1 		$1.11M Sell
117,095
-1,243
-1% -$13K ﹤0.01% 3627
2017
Q4 		$1.15M Sell
118,338
-81,280
-41% -$846K ﹤0.01% 3577
2017
Q3 		$1.33M Buy
199,618
+18,746
+10% +$134K ﹤0.01% 3516
2017
Q2 		$1.3M Buy
180,872
+100
+0.1% +$735 ﹤0.01% 3510
2017
Q1 		$1.41M Buy
180,772
+141,476
+360% +$1.06M ﹤0.01% 3487
2016
Q4 		$278K Buy
39,296
+8,820
+29% +$65K ﹤0.01% 3836
2016
Q3 		$196K Sell
30,476
-8,434
-22% -$63.6K ﹤0.01% 3906
2016
Q2 		$361K Sell
38,910
-916
-2% -$10.6K ﹤0.01% 3847
2016
Q1 		$358K Buy
39,826
+10,288
+35% +$184K ﹤0.01% 3854
2015
Q4 		$1.5M Buy
29,538
+8,946
+43% +$468K ﹤0.01% 3502
2015
Q3 		$1.03M Buy
20,592
+4,513
+28% +$385K ﹤0.01% 3620
2015
Q2 		$1.61M Buy
+16,079
New +$1.6M ﹤0.01% 3506

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group's KALV Position: Q4 2025 in Review

Vanguard Group increased its KalVista Pharmaceuticals (KALV) stake by 0.32% in Q4 2025, buying an estimated $105K and bringing the position to 2,509,020 shares worth $40.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

Vanguard Group first reported a position in KALV in Q2 2015 and has held it in 43 quarters since. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • Vanguard Group held 2,509,020 shares of KalVista Pharmaceuticals worth $40.5M as of Q4 2025.
  • Vanguard Group bought 7,901 KalVista Pharmaceuticals shares in Q4 2025, an estimated $105K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2281 holding.
  • Vanguard Group first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 43 quarters since.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.